EMP-012, now in phase I trials, targets a novel inflammatory pathway and could benefit patients regardless of baseline inflammation type, smoking status or co-morbidities. The treatment is designed for patients with limited options, particularly those who do not qualify for biologics.

GSK said the agreement supports its goal of transforming COPD care through long-acting therapies that address the underlying drivers of disease. The company will take over global development and commercialization after the phase I study, while Empirico will complete the ongoing trial.

Empirico said the collaboration validates its genetics-driven approach to target discovery and siRNA therapeutics and will accelerate the advancement of EMP-012 as a potential precision treatment for COPD and other inflammatory respiratory diseases.

COPD, a chronic condition that impairs airflow and breathing, affects around 100 million people in China and causes one million deaths annually.

The decision, made in September 2024, aims to address the growing health burden. The program, which already covers high blood pressure and diabetes, will offer free regular checkups and health management services for COPD patients. This initiative is seen as vital in improving public knowledge, as a decade-old survey revealed that only 9% of participants recognized COPD, compared to over 60% for high blood pressure and diabetes.

Yang Ting, deputy director of the National Center for Respiratory Medicine, emphasized that the inclusion of COPD in the program would promote early diagnosis and treatment. It is also expected to enhance diagnostic and treatment capabilities at local health facilities, reducing the need for patients to seek care at major hospitals.

It was also noted the importance of connecting hospital-based therapies with home-based health management to ensure better care for patients, many of whom had previously neglected medication regimens. The program likewise aims to integrate healthcare resources for respiratory diseases, including initiatives such as lung function exams for smokers to detect early signs of COPD and encourage smoking cessation.

Source: ChinaDaily